Sector News

Parexel seeking $4B sale: WSJ

May 9, 2017
Life sciences

Not a week seems to go by without a CRO sale rumor: Chiltern, INC Research and PPD (which in fact was recapitalized last week) are two of the most recent, and now the Wall Street Journal is adding Parexel to that list.

The financial news service is reporting anonymous “people familiar with the matter” as saying the CRO is up for sale; it currently has a market cap of around $3.8 billion, but a premium could see it worth over $4 billion.

The 20,000-employee Boston-area company saw its share price tick up by more than 7% yesterday on the rumor.

“The company has drawn interest from activist investors, including Corvex Management LP, which has built a sizable stake in Parexel,” according to a person familiar with the matter talking to WSJ. Parexel is not commenting on the story.

Parexel has itself been on the M&A trail, and back in February acquired contract medical affairs services provider The Medical Affairs Company (TMAC), bolstering its outsourced healthcare specialist offering.

The deal, financial terms of which were not disclosed, saw the CRO gain access to Georgia-based TMAC and its outsourced medical affairs services to biopharma and the medical device industries.

But the company, one of the major CRO players, has also had its problems, and last year its chief financial officer and senior vice president, Ingo Bank, resigned from the company just days before its fourth-quarter results were released.

Then, a few weeks later, it delayed its 10-K filing as it looked into “misappropriation of corporate funds” by an employee.

In its SEC 12b-25 filing, the company said it found out that one of its employees, who works “in one of the company’s international operations,” had apparently been misusing its money.

Back in October 2015, Parexel narrowed its outlook for fiscal 2016, reducing its revenue target by about 2% at midpoint to around $2.14 billion amid sliding profits.

The CRO had been in the process of shedding around 850 jobs during that year, with the goal of saving between $20 million and $30 million a year starting from 2016.

Covance, itself bought by LabCorp in 2015 and now subject to cuts, tried to buy Parexel 18 years ago for $671 million, but the deal was eventually called off.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).